Literature DB >> 2855780

Photodynamic therapy of malignant brain tumours: a phase I/II trial.

H Kostron1, E Fritsch, V Grunert.   

Abstract

Twenty patients bearing malignant brain tumours (18 glioblastoma multiforme, one malignant meningioma, one melanoma metastasis) were treated 25 times with photodynamic therapy (PDT)--the combination of Hematoporophyrin derivative and light at 630 nm (40-120 J/cm2). Sixteen times the PDT was followed immediately by a single dose radiation of 4 Gy of fast electrons. Conventional radiotherapy following PDT was performed in eight patients. The median survival of three patients with multiple recurrences of glioblastoma grade IV and various chemo- and radiotherapy was 5 months. Four out of 10 patients with one recurrence and prior treatment died with a median survival of 5 months, six are still living up to 12 months. Six patients with a primary glioblastoma are surviving now up to 22 months. Phototoxicity to the skin, the only side effect of PDT, was noted in five cases, but did not pose any threat to the patients. The treatment did not affect the quality of life of the patients. Our preliminary results with the photodynamic treatment of malignant gliomas indicate that PDT might be a valuable addition to our armament in the treatment of such tumours.

Entities:  

Mesh:

Year:  1988        PMID: 2855780     DOI: 10.3109/02688698808992675

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  11 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 2.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

Review 3.  NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets.

Authors:  Yixuan Zhang; Priya Murugesan; Kai Huang; Hua Cai
Journal:  Nat Rev Cardiol       Date:  2019-10-07       Impact factor: 32.419

4.  ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial.

Authors:  M Sam Eljamel; Carol Goodman; Harry Moseley
Journal:  Lasers Med Sci       Date:  2007-10-10       Impact factor: 3.161

5.  Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo.

Authors:  Qi Xie; Lin Jia; Yan-Hong Liu; Cheng-Gang Wei
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

6.  Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy.

Authors:  Liat Benayoun; Moshe Schaffer; Rotem Bril; Svetlana Gingis-Velitski; Ehud Segal; Alexsander Nevelsky; Ronit Satchi-Fainaro; Yuval Shaked
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

7.  Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial.

Authors:  Maximilien Vermandel; Clément Dupont; Fabienne Lecomte; Henri-Arthur Leroy; Constantin Tuleasca; Serge Mordon; Constantinos G Hadjipanayis; Nicolas Reyns
Journal:  J Neurooncol       Date:  2021-03-20       Impact factor: 4.130

Review 8.  Boron Neutron Capture Therapy and Photodynamic Therapy for High-Grade Meningiomas.

Authors:  Yukiko Nakahara; Hiroshi Ito; Jun Masuoka; Tatsuya Abe
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 9.  Photodynamic Therapy for the Treatment of Glioblastoma.

Authors:  Samuel W Cramer; Clark C Chen
Journal:  Front Surg       Date:  2020-01-21

10.  Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model.

Authors:  A Obwegeser; R Jakober; H Kostron
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.